

Pr **myinfla**<sup>®</sup> ER

colchicine 0.5 mg  
extended-release tablets



The first  
**0.5 mg colchicine**  
available in  
Canada\*

In adult patients with existing  
coronary artery disease

## Add Pr **MYINFLA**<sup>®</sup> to standard therapies for reduction of atherothrombotic events


MYINFLA (colchicine extended-release tablets) is indicated for the reduction of atherothrombotic events in adult patients with existing coronary artery disease, in addition to standard therapies, including LDL-C-lowering and antithrombotic drug treatment.

LDL-C: low-density lipoprotein cholesterol


\*Comparative clinical significance has not been established.

# An anti-inflammatory agent


## The mechanism of action of MYINFLA\*



Disrupts cytoskeletal functions through the inhibition of  $\beta$ -tubulin polymerization into microtubules



Results in prevention of the activation, degranulation, and migration of neutrophils



Inactivated if complex not assembled



IL-1 $\beta$

May interfere with intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediates activation of interleukin-1 $\beta$

The mechanism of action is not completely understood.

### Pharmacodynamics of MYINFLA\*

**Favourable plaque-modifying effects** of daily 0.5 mg colchicine therapy have been observed in patients with post-acute coronary syndrome.


- » Independent of substantial low-density lipoprotein reduction or high-dose statin intensification

Colchicine may **stabilize atherosclerotic plaques** and in animal models in vivo has been shown to exert cardioprotective, anti-inflammatory and anti-atherosclerotic effects.

The pharmacodynamics of colchicine in prevention of atherothrombotic cardiovascular events is not completely understood.

\*Clinical significance has not been established.

# A convenient, low-dose add-on to standard therapies, including LDL-C-lowering and antithrombotic drug treatment



## Convenient once-daily dosing



0.5 mg  
once daily



Oral  
dosing



With or  
without food

Avoid taking grapefruit or grapefruit juice with MYINFLA

Consult the Product Monograph at <https://pendopharm.com/wp-content/uploads/2022/05/MYINFLA-PM-EN.pdf> for important information about:

- Contraindications with co-administration of strong P-glycoprotein (P-gp) inhibitors or strong CYP3A4 inhibitors, in patients with severe renal (eGFR < 30 mL/min) and hepatic impairment and those with existing blood dyscrasias
  - Other relevant warnings and precautions regarding toxicity, moderate renal and hepatic impairment, gastrointestinal disorders, significant underlying gastrointestinal diseases, myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia and aplastic anemia, neuromuscular toxicity and rhabdomyolysis, pregnant or breastfeeding women, fertility risk, and teratogenic risk
  - Conditions of clinical use, adverse reactions, drug interactions, and dosage and administration
- The Product Monograph is also available by contacting our Medical Information Department at 1-888-550-6060 or [medinfo@pendopharm.com](mailto:medinfo@pendopharm.com).

eGFR: estimated glomerular filtration rate

1. MYINFLA® Product Monograph. PENDOPHARM, Division of Pharmascience Inc. August 20, 2021.

MYINFLA® and the MYINFLA logo are registered trademarks owned by Finchley Research and Development Inc., used under license by PENDOPHARM, division of Pharmascience Inc.

Made in  
Canada

**myinfla** ER  
colchicine 0.5 mg  
extended-release tablets

